LAX.SH
CONCORD BIOTECH LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
1,270.7
+0.05%52W Range
Market Cap
₹13,293.58 Cr
Traded: ₹11.91 Cr (0.09%) 0.0x
Free Float: ₹5,171.20 Cr (0.23% of FF traded)
Volume · 60D trend
93.35 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +11.0% | +7.0% | -- | -12.0% | Decelerating |
| Profit | -- | +3.0% | +4.0% | -- | -26.0% | Stable |
| Return | -- | -- | -- | -40.0% | -- | -- |
| ROE | -- | +18.0% | +18.0% | -- | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 257 | 326 | 278 | 247 | 204 | 430 | 244 | 310 | 216 | 319 | 241 | 262 | 195 | 273 | 241 | 159 |
| Expenses | 175 | 208 | 179 | 159 | 143 | 241 | 146 | 176 | 135 | 187 | 135 | 147 | 123 | 146 | 131 | 121 |
| Operating Profit | 82 | 118 | 98 | 88 | 61 | 189 | 98 | 134 | 81 | 132 | 106 | 116 | 72 | 127 | 110 | 37 |
| Other Income | 14 | 15 | 7 | 16 | 15 | 9 | 17 | 10 | 12 | 11 | 11 | 8 | 13 | 12 | 9 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 18 | 20 | 19 | 18 | 18 | 15 | 13 | 13 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 |
| Profit Before Tax | 78 | 114 | 86 | 86 | 59 | 184 | 101 | 130 | 80 | 129 | 103 | 110 | 71 | 124 | 105 | 30 |
| Tax % | 26.0% | 22.0% | 26.0% | 26.0% | 25.0% | 24.0% | 25.0% | 27.0% | 25.0% | 26.0% | 25.0% | 26.0% | 23.0% | 26.0% | 26.0% | 26.0% |
| Net Profit | 58 | 88 | 64 | 63 | 44 | 140 | 76 | 96 | 60 | 95 | 78 | 81 | 54 | 91 | 77 | 22 |
| Exceptional Items | -- | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| EPS (Rs) | 5.6 | 8.5 | 6.2 | 6.1 | 4.2 | 13.4 | 7.3 | 9.2 | 5.7 | 9.1 | 7.4 | 7.7 | 5.2 | 8.8 | 7.4 | 2.1 |
| Sales Growth (YoY) | 26.2% | -24.1% | 13.7% | -20.4% | -5.5% | 34.8% | 1.4% | 18.2% | 10.8% | 17.0% | 0.1% | 65.1% | 7.6% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 17.3% | 12.6% | 21.1% | -52.6% | 76.2% | -21.3% | 43.5% | -32.3% | 32.4% | -8.0% | 34.4% | -28.6% | 13.3% | 51.6% | -- |
| OP Growth (YoY) | 34.4% | -37.6% | 0.0% | -34.3% | -24.7% | 43.2% | -7.5% | 15.5% | 12.5% | 3.9% | -3.6% | 213.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | -30.5% | 20.4% | 11.4% | 44.3% | -67.7% | 92.9% | -26.9% | 65.4% | -38.6% | 24.5% | -8.6% | 61.1% | -43.3% | 15.5% | 197.3% | -- |
| Profit Growth (YoY) | 33.0% | -37.0% | -12.0% | -34.0% | -26.0% | 48.0% | -2.0% | 18.0% | 9.0% | 4.0% | 0.0% | 269.0% | 11.0% | -- | -- | -- |
| EPS Growth (YoY) | -- | -36.7% | -15.2% | -33.5% | -26.1% | 47.8% | -2.0% | 18.2% | 9.4% | 3.8% | 0.1% | 268.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 37.8% | 1.3% | 44.4% | -68.6% | 84.8% | -20.7% | 60.5% | -37.2% | 22.5% | -4.3% | 48.6% | -40.5% | 18.2% | 252.4% | -- |
| OP Margin | -- | 36.2% | 35.3% | 35.6% | 29.9% | 44.0% | 40.2% | 43.2% | 37.5% | 41.4% | 44.0% | 44.3% | 36.9% | 46.5% | 45.6% | 23.3% |
| Net Margin | -- | 27.0% | 23.0% | 25.5% | 21.6% | 32.6% | 31.1% | 31.0% | 27.8% | 29.8% | 32.4% | 30.9% | 27.7% | 33.3% | 31.9% | 13.8% |
| Material Cost % | -- | 26.3% | 23.7% | 19.8% | 22.1% | 29.9% | 21.5% | 24.6% | 22.4% | 27.9% | 19.6% | 20.1% | 20.7% | 20.8% | 20.5% | 22.0% |
| Employee Cost % | -- | 14.7% | 16.8% | 18.0% | 18.6% | 9.1% | 14.2% | 10.8% | 14.7% | 10.7% | 12.7% | 11.5% | 14.5% | 10.5% | 11.4% | 18.2% |
| P/S | 12.00 | 14.09 | 9.49 | 11.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 48.28 | 56.97 | 35.19 | 39.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.59 | 7.37 | 6.02 | 6.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....
In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading ....
The Board of Director at its meeting held today i.e. Wednesday, September 23, 2026, has inter-alia considered and approved Issuance of Bonus shares & Increase in the Authorised Share Capital ....
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/09/2026 ,inter alia, to consider and approve the proposal for declaration ....
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II - Valthera Formulation Facility of the Company.
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time ....
We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.
Transcript of Q1 - FY27 Earnings call held on August 03, 2026
Pursuant to regulation 44(3) of the SEBI (LODR) Regulations, 2015 and section 108 of the Companies Act, 2013, the voting results along with the scrutinizers report for the business items ....
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.
Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting information
The register of members and share transfer book of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026. Further the Company has fixed Friday, July 24, 2026 ....
Annual Report for the financial year 2025-26
Business Responsibility and Sustainability Report for financial year 2025-26
The Notice of 41st Annual General Meeting of the Company of scheduled to be held on Friday, July 31, 2026 through Video Conferencing (VC) / Other Audio-visual means(OAVM) at 12:00 Noon ....
Newspaper advertisement for Notice of 41st Annual General Meeting.
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate dated July 01, 2026 issued by MUFG Intime India Private Limited ....
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s code of conduct for Regulating, Monitoring and Reporting ....
We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation ....
We are pleased to announce that the Company has entered into an agreement to Invest in M/s. FSGE Renewable Power Private Limited for installation of Wind Solar Hybrid Power Project having ....
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, scheduled to be held on 24th & 25th June, 2026.
Intimation of Schedule of Analyst / Institutional Investor meeting to be held on June 17, 2026 at 10:30 AM
We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection ....
We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg.
Transcript of Q4 & FY26 Earnings call held on June 01, 2026
We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Earning Call Recording- For the Quarter and financial year ended on March 31, 2026
Extracts of newspaper publications dated May 30, 2026 of the audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.
Pursuant to Regulation 30 and Schedule III part A of SEBI Listing Regulations, Investor Presentation on audited Standalone and Consolidated Financial Results for the quarter and financial ....
Outcome of Board Meeting held today i.e. Friday, May 29, 2026 wherein the Board inter-alia considered and approved Audited Financial results and statements for the Financial Year ended ....
The Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026 appointed Mrs. Ekta Gupta as Independent Director(Additional) of the company.
Audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended on March 31, 2026
Appointment of Cost Auditors and Internal Auditors
The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
The Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the audited Standalone and Consolidated Financial Results of the Company for the quarter and financial ....
Pursuant to the regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed Annual Secretarial Compliance Report for the financial year ended ....
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited Standalone and ....
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026 as received from RTA of the Company.
In Continuation to our intimation dated November 13, 2025, we are pleased to announce Investment in Celliimune Biotech Private Limited.
The trading window for trading in the Equity Shares by the Designated Persons of the Company will be closed from 1st April, 2026 till the expiry of 48 hours after the declaration of the ....
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 scheduled to be held on March 06, 2026.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 scheduled to be held on 26th February 2026.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 scheduled to be held on 25th February 2026.
Transcript of Q3 & Nine months FY26 Earnings call held on February 12, 2026
Q3FY26 Earnings Call Audio
Newspaper Publication cutouts Q3 - FY 2025-26
Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months ended on December 31, 2025.
Modified list of KMP''s to determine materiality of an event or information and for making disclosure with stock exchanges.
Credit Ratings
6Concalls
12Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Sep 2023
30 Sept 2023Sep 2023
30 Sept 2023Held by ETFs
13 ETFs hold concordbio · sorted by weight
Held by Mutual Funds
33 schemes hold concordbio · sorted by weight